<DOC>
	<DOC>NCT00312130</DOC>
	<brief_summary>This is an exploratory study to assess whether vildagliptin, an unapproved drug, can increase insulin secretion in subjects with pre-diabetes who have a defect in the insulin response and elevated levels of fasting glucose.</brief_summary>
	<brief_title>A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes</brief_title>
	<detailed_description />
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>BMI in the range 2245 and with a stable weight for the last 6 months Blood glucose criteria must be met Written informed consent Pregnancy or lactation Previous diagnosis of type 2 diabetes or treatment with hypoglycemic agents Type 1 diabetes Evidence of cardiovascular complications as defined by the protocol Evidence of diabetic complications as defined by the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Vildaglptin</keyword>
	<keyword>Pre-diabetes</keyword>
</DOC>